

Oncology Clinical Pathways

Mesothelioma

October 2024 – V3.2024



Choose **VA**



SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Table of Contents

- [Presumptive Conditions](#).....3
- [Pleural Epithelioid](#).....4
- [Sarcomatoid or Biphasic](#).....5
- [Molecular Testing Table](#).....6



Mesothelioma – Presumptive Conditions

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

Mesothelioma is not currently listed as a presumptive condition.

For more information, please visit [U.S. Department of Veterans Affairs - Presumptive Disability Benefits \(va.gov\)](https://www.va.gov/opa/whatsnew/presumptive-disability-benefits)



Choose **VA**




SHOULDER to SHOULDER
Every Step of the Way

VA



U.S. Department
of Veterans Affairs

Mesothelioma – Pleural Epithelioid



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

*** Pleural Epithelioid** comprehensive genomic profiling (CGP) and PD-L1 expression is not routinely recommended in mesothelioma


Refer to Genetics for Counseling germline BAP1 alterations have been described in patients with mesothelioma; referral to genetics is recommended

Candidate for Bevacizumab if ECOG PS 0-2; not amenable to curative surgery; due to anti-VEGF effects patients with the following should not receive bevacizumab: non-healing wound/fracture, major surgery in prior 4 weeks, bleeding disorder or coagulopathy, recent history of GI perforation, unstable cardiac condition [uncontrolled HTN, arterial thromboembolism, symptomatic CHF (NYHA II-IV), recent MI or CVA, uncontrolled angina or arrhythmia], use of antiplatelet therapy (aspirin ≥325 mg/day, dipyridol, ticlopidine, dipyridamole), anti-vitamin K drugs at curative dose, LMWH at curative dose, use of NSAIDS

Pleurectomy patient a candidate if N0 disease, low burden pleural disease, limited chest wall involvement

Progression if patient is symptomatic, consider referral to Radiation Oncology for palliative therapy

Mesothelioma – Sarcomatoid or Biphasic



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

^a **Sarcomatoid or Biphasic** comprehensive genomic profiling (CGP) and PD-L1 expression is not routinely recommended in mesothelioma
^b **Refer to Genetics for Counseling** germline BAP1 alterations have been described in patients with mesothelioma; referral to genetics is recommended
^c **Ipilimumab** dosing of 1mg/kg every 6 weeks
^d **Progression** if patient is symptomatic, consider referral to Radiation Oncology for palliative therapy

Mesothelioma – Molecular Testing Table

Eligibility	Test Category	Test Type	Recommended Vendors	NPOP Coverage	Specimen Type
Mesothelioma	No molecular testing is currently required for standard prognostication and therapy.				

